Xeris Pharmaceuticals Inc (XERS) Receives a Buy from Mizuho Securities


In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals Inc (XERS), with a price target of $27. The company’s shares closed yesterday at $9.84, close to its 52-week low of $9.21.

Yang wrote:

“We believe this financing is positive for a number of reasons: 1) Provides financing through 2022, by which time we believe Xeris can be cash break-even; 2) Allows management to focus on the Gvoke HypoPen launch, 3) Avoids the potential pitfall of “short the launch” phenomenon, 4) Creates opportunities for higher long-term growth by optimal upfront investment in the company. We maintain our Buy rating and $27 PT assuming Gvoke Hypopen NDA approval in ~50% market share 6-7 years post launch.”

According to TipRanks.com, Yang is a 5-star analyst with an average return of 15.8% and a 47.4% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xeris Pharmaceuticals Inc with a $27 average price target.

See today’s analyst top recommended stocks >>

Based on Xeris Pharmaceuticals Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $14.77 million. In comparison, last year the company had a GAAP net loss of $7.53 million.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Xeris Pharmaceuticals, Inc.is a pharmaceutical company. It offers XeriSol™ and XeriJect™ formulation technologies. The firm focuses on the development of patient-friendly injectable drugs to address unmet medical needs. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts